KRT17 (Keratin, type I cytoskeletal 17) variants and mutations
KRT17 (also known as Keratin, type I cytoskeletal 17) is a human protein-coding gene encoding a keratin, type I cytoskeletal 17 protein. It supports structural integrity of nail beds, hair follicles, glands, and stressed epithelia and also influences epithelial growth responses. Dominant pathogenic variants cause pachyonychia congenita and steatocystoma multiplex. This analysis covers 839 KRT17 variants and mutations. Of these, 83% have computational variant effect predictions. Disease context includes pachyonychia congenita 2, sebocystomatosis, and pachyonychia congenita. Example KRT17 variants include M1T, T2N, and T3A.
Variant analysis overview
- Gene: KRT17
- Protein: Keratin, type I cytoskeletal 17
- UniProt accession: Q04695
- Organism: Homo sapiens
- Variants analyzed: 839
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 572 unspecified-consequence records; 110 synonymous variants; 127 missense variants; 6 stop-gained variants; 3 in-frame deletions; 15 frameshift variants; 5 splice-region variants; 1 stop retained variant; 1 in-frame insertions; 1 substitution
- Prediction scores: 696 variants have prediction scores (83% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: pachyonychia congenita 2, sebocystomatosis, pachyonychia congenita, hereditary disease, nonsyndromic congenital nail disorder 4, Abnormality of the skin, ovarian dysfunction, temporomandibular joint disorder, sialolithiasis, psoriasis, neoplasm, cancer.
Protein structure and variant hotspots
- Protein features: 1 domains; 9 post-translational modification sites.
- Structural context: 589 variants have structural context.
- PTM context: 15 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable KRT17 variants
Examples include M1T, T2N, T3A, T3P, S4F, S4P, S4T, I5M. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs760546497, ClinGen CA8563889, ClinVar RCV002580486, MetaLR 0.43, MetaSVM -0.08, Uncertain significance, not provided
- T2N (p.Thr2Asn), gnomAD rs1234293016, REVEL 0.29, CADD 22.60
- T3A (p.Thr3Ala), TOPMed rs1219056740, gnomAD rs1219056740
- T3P (p.Thr3Pro), TOPMed rs1219056740, gnomAD rs1219056740, REVEL 0.49, CADD 26.00
- S4F (p.Ser4Phe), gnomAD rs1235064745, REVEL 0.23, CADD 23.30, Uncertain significance, Inborn genetic diseases
- S4P (p.Ser4Pro), 1000Genomes rs11553458, ESP rs11553458, ExAC rs11553458, TOPMed rs11553458, Benign
- S4T (p.Ser4Thr), rs11553458, ClinGen CA8563887, ClinVar RCV002090650, ClinVar RCV004731231, REVEL 0.20, CADD 18.10, Benign, not provided
- I5M (p.Ile5Met), ExAC rs761633581, TOPMed rs761633581, gnomAD rs761633581, REVEL 0.22, CADD 23.40
- I5N (p.Ile5Asn), gnomAD rs1286509362, REVEL 0.11, CADD 21.80
- I5T (p.Ile5Thr), gnomAD rs1286509362, REVEL 0.13, CADD 20.70
- I5V (p.Ile5Val), TOPMed rs1327072340, gnomAD rs1327072340, REVEL 0.14, CADD 19.70
- R6C (p.Arg6Cys), rs79896664, ClinGen CA8563885, ClinVar RCV000961490, 1000Genomes rs79896664, REVEL 0.55, CADD 24.50, Likely benign, not provided
- R6H (p.Arg6His), ExAC rs768150902, TOPMed rs768150902, gnomAD rs768150902, REVEL 0.33, CADD 21.80
- Q7R (p.Gln7Arg), 1000Genomes rs553672396, ExAC rs553672396, TOPMed rs553672396, gnomAD rs553672396, REVEL 0.19, CADD 22.00
- F8L (p.Phe8Leu), gnomAD rs1908662186, REVEL 0.19, CADD 22.60
- T9N (p.Thr9Asn), ExAC rs769369981, TOPMed rs769369981, REVEL 0.15, CADD 22.40
- S11C (p.Ser11Cys), TOPMed rs1908661814, REVEL 0.52, CADD 27.60
- S12G (p.Ser12Gly), TOPMed rs1266296732, gnomAD rs1266296732, REVEL 0.19, CADD 15.60
- S12N (p.Ser12Asn), Ensembl rs1908661638, REVEL 0.22, CADD 21.40
- S13C (p.Ser13Cys), 1000Genomes rs2144617152
- K15R (p.Lys15Arg), rs1177336937, ClinGen CA399513880, ClinVar RCV002831641, TOPMed rs1177336937, REVEL 0.19, CADD 19.80, Uncertain significance, Inborn genetic diseases
- G16A (p.Gly16Ala), ExAC rs781364097, TOPMed rs781364097, gnomAD rs781364097, REVEL 0.34, CADD 22.10
- G16D (p.Gly16Asp), ExAC rs781364097, TOPMed rs781364097, gnomAD rs781364097, REVEL 0.43, CADD 23.90
- G16V (p.Gly16Val), ExAC rs781364097, TOPMed rs781364097, gnomAD rs781364097
- S17F (p.Ser17Phe), NCI-TCGA Cosmic COSV6086, REVEL 0.34, CADD 17.20, Variant assessed as somatic; moderate impact.
- S18F (p.Ser18Phe), gnomAD rs1409637177, REVEL 0.25, CADD 22.90
- S18Y (p.Ser18Tyr), gnomAD rs1409637177, REVEL 0.38, CADD 20.30
- G19R (p.Gly19Arg), 1000Genomes rs558623005, ExAC rs558623005, TOPMed rs558623005, gnomAD rs558623005, REVEL 0.54, CADD 17.60
- G19S (p.Gly19Ser), 1000Genomes rs558623005, ExAC rs558623005, TOPMed rs558623005, gnomAD rs558623005, REVEL 0.27, CADD 10.60
- L20V (p.Leu20Val), ExAC rs752754536, TOPMed rs752754536, gnomAD rs752754536, REVEL 0.24, CADD 10.60
- G21A (p.Gly21Ala), ExAC rs765583417, TOPMed rs765583417, gnomAD rs765583417, REVEL 0.31, CADD 17.00, Uncertain significance
- G21E (p.Gly21Glu), rs765583417, ClinGen CA290686318, ClinVar RCV003201465, ExAC rs765583417, REVEL 0.56, CADD 23.60, Uncertain significance, Inborn genetic diseases
- G21R (p.Gly21Arg), gnomAD rs1366910575, REVEL 0.50, CADD 24.10
- G21W (p.Gly21Trp), gnomAD rs1366910575
- G22D (p.Gly22Asp), ExAC rs759780535, gnomAD rs759780535, REVEL 0.48, CADD 23.50
- G22R (p.Gly22Arg), TOPMed rs1387497386, gnomAD rs1387497386, REVEL 0.56, CADD 22.80
- G23A (p.Gly23Ala), rs1309344989, gnomAD rs1309344989, REVEL 0.26, CADD 16.90, Variant assessed as somatic; moderate impact.
- G23S (p.Gly23Ser), rs750279151, ClinGen CA8563866, NCI-TCGA Cosmic COSV1002, ClinVar RCV003079118, REVEL 0.19, CADD 16.50, Likely benign, not provided
- S24L (p.Ser24Leu), rs367544262, ESP rs367544262, ExAC rs367544262, TOPMed rs367544262, REVEL 0.47, CADD 21.40, Variant assessed as somatic; moderate impact.
- S25F (p.Ser25Phe), Ensembl rs1908658723
- S25P (p.Ser25Pro), rs1443619298, gnomAD rs1443619298, REVEL 0.45, CADD 25.20, Variant assessed as somatic; moderate impact.
- S25Y (p.Ser25Tyr), Ensembl rs1908658723, REVEL 0.54, CADD 24.40
- R26C (p.Arg26Cys), 1000Genomes rs374384105, ESP rs374384105, ExAC rs374384105, TOPMed rs374384105, REVEL 0.43, CADD 23.30
- R26H (p.Arg26His), ExAC rs745486930, TOPMed rs745486930, gnomAD rs745486930, REVEL 0.39, CADD 18.80
- R26L (p.Arg26Leu), ExAC rs745486930, TOPMed rs745486930, gnomAD rs745486930, REVEL 0.24, CADD 16.80
- T27I (p.Thr27Ile), 1000Genomes rs554504293, ExAC rs554504293, TOPMed rs554504293, gnomAD rs554504293, REVEL 0.20, CADD 15.60, Uncertain significance, Inborn genetic diseases
- T27N (p.Thr27Asn), 1000Genomes rs554504293, ExAC rs554504293, TOPMed rs554504293, gnomAD rs554504293, REVEL 0.20, CADD 16.10
- T27P (p.Thr27Pro), Ensembl rs1597693301
- S28F (p.Ser28Phe), NCI-TCGA Cosmic COSV6086, Variant assessed as somatic; moderate impact.
- S28T (p.Ser28Thr), Ensembl rs1908657901, REVEL 0.29, CADD 21.50
- C29R (p.Cys29Arg), ESP rs371000502, ExAC rs371000502, TOPMed rs371000502, gnomAD rs371000502, REVEL 0.19, CADD 18.20
- R30P (p.Arg30Pro), rs2229512, ClinGen CA8563852, ClinVar RCV003222912, 1000Genomes rs2229512, REVEL 0.52, CADD 18.90, Benign/Likely benign, not provided
- R30Q (p.Arg30Gln), rs2229512, ClinGen CA8563853, ClinVar RCV002966704, 1000Genomes rs2229512, REVEL 0.20, CADD 17.10, Likely benign, not provided
- R30W (p.Arg30Trp), ExAC rs747613789, TOPMed rs747613789, gnomAD rs747613789, REVEL 0.47, CADD 17.50
- L31P (p.Leu31Pro), TOPMed rs1908657322
- S32T (p.Ser32Thr), TOPMed rs1295462977, gnomAD rs1295462977, REVEL 0.11, CADD 15.30
- G34D (p.Gly34Asp), rs368662815, ClinGen CA8563849, ClinVar RCV004412204, ClinVar RCV004780708, REVEL 0.25, CADD 16.80, Uncertain significance, not provided; Inborn genetic diseases
- G34S (p.Gly34Ser), ExAC rs758929957, TOPMed rs758929957, gnomAD rs758929957, REVEL 0.11, CADD 8.55
- G34V (p.Gly34Val), 1000Genomes rs368662815, ExAC rs368662815, gnomAD rs368662815, REVEL 0.22, CADD 15.40, Uncertain significance
- G36V (p.Gly36Val), ExAC rs755266373, TOPMed rs755266373, gnomAD rs755266373, REVEL 0.46, CADD 19.20
- A37D (p.Ala37Asp), gnomAD rs1311792391
- A37G (p.Ala37Gly), gnomAD rs1311792391
- A37V (p.Ala37Val), gnomAD rs1311792391, REVEL 0.22, CADD 5.68
- G38S (p.Gly38Ser), ExAC rs757015302, TOPMed rs757015302, gnomAD rs757015302, REVEL 0.23, CADD 17.00
- S39F (p.Ser39Phe), ExAC rs764050721, TOPMed rs764050721, gnomAD rs764050721, REVEL 0.55, CADD 24.30
- S39P (p.Ser39Pro), TOPMed rs1043719695, REVEL 0.25, CADD 20.80
- L42M (p.Leu42Met), TOPMed rs1908655261
- L42P (p.Leu42Pro), rs375582148, ClinGen CA8563839, ClinVar RCV003734048, ESP rs375582148, REVEL 0.37, CADD 20.40, Likely benign, not provided
- G43E (p.Gly43Glu), NCI-TCGA Cosmic COSV6086, Variant assessed as somatic; moderate impact.
- G43R (p.Gly43Arg), TOPMed rs1908655000
- S44F (p.Ser44Phe), ExAC rs775031648, gnomAD rs775031648, REVEL 0.19, CADD 19.30
- G47A (p.Gly47Ala), rs759301828, ClinGen CA399513407, ClinVar RCV002302193, REVEL 0.32, CADD 16.40, Uncertain significance, not provided
- G47S (p.Gly47Ser), rs1294947365, NCI-TCGA Cosmic COSV6086, TOPMed rs1294947365, gnomAD rs1294947365, REVEL 0.28, CADD 13.20, Variant assessed as somatic; moderate impact.
- G47V (p.Gly47Val), ExAC rs759301828, gnomAD rs759301828, REVEL 0.50, CADD 17.40
- G49R (p.Gly49Arg), gnomAD rs1430218782
- T51A (p.Thr51Ala), 1000Genomes rs201047424, ExAC rs201047424, TOPMed rs201047424, gnomAD rs201047424, REVEL 0.18, CADD 1.81, Likely benign, not provided
- T51N (p.Thr51Asn), TOPMed rs1482978208, gnomAD rs1482978208, REVEL 0.17, CADD 2.58
- T51S (p.Thr51Ser), 1000Genomes rs201047424, ExAC rs201047424, TOPMed rs201047424, gnomAD rs201047424, REVEL 0.16, CADD 1.04
- L52F (p.Leu52Phe), ExAC rs773659419, TOPMed rs773659419, gnomAD rs773659419, REVEL 0.14, CADD 9.04
- L52V (p.Leu52Val), ExAC rs773659419, TOPMed rs773659419, gnomAD rs773659419, REVEL 0.08, CADD 8.27
- G53R (p.Gly53Arg), rs748631498, ClinGen CA399513326, ClinVar RCV003878541, ExAC rs748631498, REVEL 0.32, CADD 18.40, Benign, not provided
- G54V (p.Gly54Val), 1000Genomes rs570711033, ExAC rs570711033, TOPMed rs570711033, gnomAD rs570711033, REVEL 0.34, CADD 12.70
- S56R (p.Ser56Arg), ExAC rs754997516, TOPMed rs754997516, gnomAD rs754997516, REVEL 0.32, CADD 16.90
- Y57D (p.Tyr57Asp), gnomAD rs1311238669
- S58C (p.Ser58Cys), rs1355547921, NCI-TCGA Cosmic COSV6086, gnomAD rs1355547921, REVEL 0.27, CADD 21.10, Variant assessed as somatic; moderate impact.
- S58F (p.Ser58Phe), NCI-TCGA Cosmic COSV6086, REVEL 0.37, CADD 21.70, Variant assessed as somatic; moderate impact.
- C60F (p.Cys60Phe), ESP rs200841795, ExAC rs200841795, TOPMed rs200841795, gnomAD rs200841795, REVEL 0.21, CADD 20.60, Likely benign
- C60S (p.Cys60Ser), rs200841795, ClinGen CA8563824, ClinVar RCV001470161, ESP rs200841795, REVEL 0.22, CADD 18.20, Likely benign, not provided
- C60C (p.Cys60Cys), gnomAD 17-41620468-G-A, CADD 6.11
- Y61C (p.Tyr61Cys), ESP rs142502852, ExAC rs142502852, TOPMed rs142502852, gnomAD rs142502852
- Y61F (p.Tyr61Phe), ESP rs142502852, ExAC rs142502852, TOPMed rs142502852, gnomAD rs142502852
- S62C (p.Ser62Cys), rs11553455, ClinGen CA8563822, ClinVar RCV003878540, ExAC rs11553455, REVEL 0.33, CADD 22.60, Benign, not provided
- S62G (p.Ser62Gly), ExAC rs11553455, gnomAD rs11553455, Benign
- S62I (p.Ser62Ile), TOPMed rs1190242046, gnomAD rs1190242046, REVEL 0.41, CADD 18.20
- S62R (p.Ser62Arg), ExAC rs763856669, gnomAD rs763856669, REVEL 0.46, CADD 22.10
- F63L (p.Phe63Leu), TOPMed rs1421493202, gnomAD rs1421493202, REVEL 0.41, CADD 0.76
- S65C (p.Ser65Cys), TOPMed rs765464535, gnomAD rs765464535, REVEL 0.24, CADD 17.40
- S65F (p.Ser65Phe), TOPMed rs765464535, gnomAD rs765464535, REVEL 0.18, CADD 15.40
- G66S (p.Gly66Ser), TOPMed rs1477627658, gnomAD rs1477627658, REVEL 0.39, CADD 20.70
- G68D (p.Gly68Asp), rs752629599, ClinGen CA8563819, ClinVar RCV002667441, ExAC rs752629599, AlphaMissense 0.33, MetaLR 0.51, Uncertain significance, not provided
- G68V (p.Gly68Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Y69F (p.Tyr69Phe), TOPMed rs1412586091
- Y69* (p.Tyr69Ter), rs1227678934, gnomAD 17-41620528-A-T, CADD 10.90
- Y69H (p.Tyr69His), rs199861227, gnomAD 17-41620530-A-G, CADD 12.00
- Y69D (p.Tyr69Asp), rs199861227, gnomAD 17-41620530-A-C, CADD 12.50
- G70D (p.Gly70Asp), NCI-TCGA Cosmic COSV6086, cosmic curated COSV60861, Variant assessed as somatic; moderate impact.
- G70S (p.Gly70Ser), gnomAD rs1482183368, REVEL 0.18, CADD 16.50
- G70G (p.Gly70Gly), rs751031889, gnomAD 17-41620519-G-T, CADD 7.25
- G70A (p.Gly70Ala), gnomAD 17-41620520-C-G, CADD 6.23
- S71G (p.Ser71Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S71R (p.Ser71Arg), rs371521134, ClinGen CA8563818, ClinVar RCV002980651, ESP rs371521134, REVEL 0.20, CADD 17.70, Uncertain significance, Inborn genetic diseases
- S72G (p.Ser72Gly), gnomAD rs1196700871, REVEL 0.12, CADD 15.40
- S72S (p.Ser72Ser), rs764220511, gnomAD 17-41620483-G-A, CADD 2.34
- p.Phe72 Cys88del, gnomAD 17-41620466-CAGCA, CADD 5.83
- F73F (p.Phe73Phe), rs191217038, gnomAD 17-41620516-G-A, CADD 6.09
- G74R (p.Gly74Arg), ESP rs368097553, ExAC rs368097553, REVEL 0.53, CADD 23.70
- G74V (p.Gly74Val), ExAC rs200102896, TOPMed rs200102896, gnomAD rs200102896, REVEL 0.46, CADD 14.00
- G74G (p.Gly74Gly), gnomAD 17-41620513-G-C, CADD 0.89
- G74S (p.Gly74Ser), rs1238831127, gnomAD 17-41620515-C-T, CADD 6.93
- G75D (p.Gly75Asp), ExAC rs760378776, gnomAD rs760378776, REVEL 0.10, CADD 15.20
- G75S (p.Gly75Ser), rs1294575047, TOPMed rs1294575047, gnomAD rs1294575047, REVEL 0.14, CADD 10.00, Variant assessed as somatic; moderate impact.
- G75V (p.Gly75Val), ExAC rs760378776, gnomAD rs760378776, REVEL 0.15, CADD 10.30, Uncertain significance, Inborn genetic diseases
- G75G (p.Gly75Gly), gnomAD 17-41620504-A-G, CADD 1.99
- G75A (p.Gly75Ala), rs1383629214, gnomAD 17-41620508-C-G, CADD 8.24
- G75E (p.Gly75Glu), gnomAD 17-41620508-C-T, CADD 8.63
- G75W (p.Gly75Trp), gnomAD 17-41620509-C-A, CADD 5.92
- V76G (p.Val76Gly), Ensembl rs1908649737
- V76I (p.Val76Ile), gnomAD rs1329150569, REVEL 0.10, CADD 5.20
- V76V (p.Val76Val), rs770190838, gnomAD 17-41620498-C-A, CADD 0.56
- V76M (p.Val76Met), rs575886189, gnomAD 17-41620500-C-T, CADD 2.97
- D77G (p.Asp77Gly), TOPMed rs1218892088, gnomAD rs1218892088, REVEL 0.20, CADD 19.00
- G78A (p.Gly78Ala), 1000Genomes rs11553454, ExAC rs11553454, TOPMed rs11553454, gnomAD rs11553454
- G78E (p.Gly78Glu), 1000Genomes rs11553454, ExAC rs11553454, TOPMed rs11553454, gnomAD rs11553454, REVEL 0.54, CADD 23.00
- L79M (p.Leu79Met), TOPMed rs1028399478, gnomAD rs1028399478
- L80P (p.Leu80Pro), Ensembl rs1313304776
- A81D (p.Ala81Asp), ExAC rs769139580, TOPMed rs769139580, gnomAD rs769139580, REVEL 0.14, CADD 5.79
- A81V (p.Ala81Val), ExAC rs769139580, TOPMed rs769139580, gnomAD rs769139580, REVEL 0.11, CADD 3.98, Uncertain significance, Inborn genetic diseases
- G82E (p.Gly82Glu), TOPMed rs1908648959, REVEL 0.47, CADD 21.60, Uncertain significance, Inborn genetic diseases
- G82R (p.Gly82Arg), rs2543827877, ClinGen CA399512694, NCI-TCGA Cosmic COSV6086, ClinVar RCV003863430, Uncertain significance, not provided
- G82V (p.Gly82Val), gnomAD 17-41620477-AGGTG, CADD 6.55
- G82G (p.Gly82Gly), gnomAD 17-41620486-G-A, CADD 9.07
- G82D (p.Gly82Asp), rs1378330109, gnomAD 17-41620487-C-T, CADD 8.30
- G82S (p.Gly82Ser), rs368104564, gnomAD 17-41620488-C-T, CADD 11.00
- G83S (p.Gly83Ser), TOPMed rs1194441798, gnomAD rs1194441798, REVEL 0.26, CADD 1.99
- G83V (p.Gly83Val), NCI-TCGA Cosmic COSV1002, cosmic curated COSV10024, Ensembl rs1908648859, Variant assessed as somatic; moderate impact.
- G83D (p.Gly83Asp), rs1174445296, gnomAD 17-41620463-C-T, CADD 1.92
- E84G (p.Glu84Gly), gnomAD rs1363382784, REVEL 0.88, CADD 31.00
- K85R (p.Lys85Arg), rs1172255841, gnomAD 17-41620532-T-C, CADD 23.60
- K85E (p.Lys85Glu), rs1908499999, gnomAD 17-41620533-T-C, CADD 17.90
- K85* (p.Lys85Ter), rs1397088965, gnomAD 17-41620533-T-TA, CADD 23.60
- A86D (p.Ala86Asp), TOPMed rs1908648465
- A86T (p.Ala86Thr), TOPMed rs1421175248, gnomAD rs1421175248, REVEL 0.27, CADD 21.80
- A86V (p.Ala86Val), rs1333332337, gnomAD 17-41620475-G-A, CADD 7.38
- A86S (p.Ala86Ser), gnomAD 17-41620476-C-A, CADD 6.49
- T87I (p.Thr87Ile), gnomAD rs1265695783, REVEL 0.84, CADD 27.70
- T87T (p.Thr87Thr), gnomAD 17-41620489-T-A, CADD 5.06
- T87A (p.Thr87Ala), gnomAD 17-41620491-T-C, CADD 2.75
- M88I (p.Met88Ile), TOPMed rs1205697518, gnomAD rs1205697518, REVEL 0.80, CADD 24.20
- M88K (p.Met88Lys), rs28928898, ClinGen CA216605, ClinVar RCV000056507, UniProt VAR 072441, AlphaMissense 0.17, not provided
- M88T (p.Met88Thr), rs28928898, ClinGen CA216606, ClinVar RCV000015696, ClinVar RCV000056508, AlphaMissense 0.17, Pathogenic, Pachyonychia congenita 2
- Q89H (p.Gln89His), ExAC rs746060683, TOPMed rs746060683, gnomAD rs746060683, REVEL 0.73, CADD 25.40
- Q89R (p.Gln89Arg), TOPMed rs1171786524, REVEL 0.90, CADD 26.40
- N90H (p.Asn90His), gnomAD rs1469282035, REVEL 0.49, CADD 23.90
- L91F (p.Leu91Phe), Ensembl rs1908647839
- L91P (p.Leu91Pro), UniProt VAR 072442, Pathogenic, in PC2
- N92D (p.Asn92Asp), rs28928896, ClinGen CA216607, ClinVar RCV000015688, ClinVar RCV000056510, REVEL 0.94, AlphaMissense 0.99, Pathogenic, not provided
- N92H (p.Asn92His), rs28928896, ClinGen CA124153, ClinVar RCV000015691, ClinVar RCV000056509, AlphaMissense 0.99, MetaLR 0.96, Pathogenic, Steatocystoma multiplex
- N92S (p.Asn92Ser), rs59151893, ClinGen CA216610, ClinVar RCV000015689, ClinVar RCV000056512, REVEL 0.91, CADD 26.20, Pathogenic, Pachyonychia congenita 2; Steatocystoma multiplex; not provided
- R94C (p.Arg94Cys), rs58730926, ClinGen CA124156, NCI-TCGA Cosmic COSV6086, ClinVar RCV000015694, REVEL 0.86, CADD 24.60, Pathogenic, Inborn genetic diseases; not provided; Steatocystoma multiplex
- R94H (p.Arg94His), rs28928897, ClinGen CA124154, NCI-TCGA Cosmic COSV6086, ClinVar RCV000015692, REVEL 0.94, AlphaMissense 0.90, Pathogenic/Likely pathogenic, Steatocystoma multiplex; Pachyonychia congenita 2; not provided
- R94P (p.Arg94Pro), rs28928897, ClinGen CA216613, ClinVar RCV000015698, ClinVar RCV000056516, AlphaMissense 0.90, MetaLR 0.92, Pathogenic, Pachyonychia congenita 2
- R94G (p.Arg94Gly), gnomAD 17-41620443-TG-T, CADD 4.83
- R94K (p.Arg94Lys), gnomAD 17-41620451-C-CT, CADD 7.16
- R94R (p.Arg94Arg), rs1357002375, gnomAD 17-41620452-T-G, CADD 9.10
- R94W (p.Arg94Trp), rs1357002375, gnomAD 17-41620452-T-A, CADD 8.94
- R94T (p.Arg94Thr), gnomAD 17-41620460-C-G, CADD 6.45
- L95P (p.Leu95Pro), rs28928899, ClinGen CA216615, ClinVar RCV000015700, ClinVar RCV000056518, AlphaMissense 1.00, MetaLR 0.94, Pathogenic, not provided
- L95Q (p.Leu95Gln), rs28928899, ClinGen CA216614, ClinVar RCV000015699, ClinVar RCV000056517, AlphaMissense 1.00, MetaLR 0.94, Pathogenic, Pachyonychia congenita 2
- A96S (p.Ala96Ser), ExAC rs754891141, TOPMed rs754891141, gnomAD rs754891141, REVEL 0.86, CADD 25.50
- S97G (p.Ser97Gly), rs1304366731, gnomAD 17-41620440-T-C, CADD 0.93
Public KRT17 analysis runs
- KRT17 analysis run — KRT17 (839 variants) — completed 2026-08-22